The table below shows Foghorn Therapeutics Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$30.91M
$22.60M
$34.16M
$19.23M
$1.32M
$430.00K
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$85.47M
$94.53M
$109.69M
$105.62M
$80.33M
$57.72M
SG&A
$27.55M
FHTX annual revenue (10-K history)
Foghorn Therapeutics Inc. reported annual revenue of $30.91M for fiscal year 2025. That is up 36.8% from $22.60M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $430.00K (FY 2020) to $30.91M. Figures come from the company's audited annual reports as filed with the SEC.